TOKYO and CAMBRIDGE, Mass., May 28, 2024 – (JCN Newswire) – Eisai Co., Ltd. and Biogen Inc. announced today that the Ministry of Food and Drug Safety (MFDS) in South Korea has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI” (lecanemab) for treatment in adult patients with mild cognitive impairment due to Alzheimer’s disease (AD) or mild AD (early AD).LEQEMBI selectively binds to soluble Aβ aggregates (protofibrils*…
